Sidewinder Therapeutics Raises $137M Series B

Sidewinder Therapeutics raised $137 million in a Series B financing round to advance newer antibody-drug conjugates, or ADCs, into clinical testing. The company is developing bispecific ADCs designed to recognize and bind to protein combinations highly expressed on cancer cells.

Sidewinder plans to focus on cancer indications including colorectal tumors and squamous cell carcinomas, and expects to push its lead program into clinical development in 2027. Founded in 2023, the company has raised $162 million in total including this round.